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Abstract
Objectives: The aim of the present study is to compare cardiovascular safety profiles of two dental anesthetics: 
articaine versus two standard mepivacaine solutions used during etiological periodontal treatment in cardiovas-
cular patients. 
Study Design: Using a cross-over study design, ten cardiovascular patients were randomly assigned to dental treatment 
with 1.8mL of a local anesthetic injected on each quadrant of the mouth: Articaine (40mg with Epinephrine 0.5mg % 
and 40mg with Epinephrine 1mg %) or Mepivacaine (30mg and 20mg with Epinephrine 1mg %). A computer program-
me enabled continuous longitudinal data collection: O2 saturation, blood pressure (BP) and heart rate (HR).
Results: No severe clinical side effects were observed. During the treatment period, we observed statistically 
significant differences as regards HR between injections with and without adrenalin (p< 0.039) and as regards 
systolic (p< 0.046) and diastolic (p < 0.046) blood pressure during the stabilization period. In both cases, the para-
meters under study increase. Age, gender, jaw treated, treatment duration and the rest of cardiovascular variables 
did not affect the results. None of the patients underwent ischemic alterations or any other complication derived 
from the treatment or the anesthesia.
Conclusions: According to the results of our study, dental anesthetics with standard concentrations of Epinephrine 
seem to alter HR and BP.  Although no cardiac ischemic alterations or any other cardiovascular complications 
have been observed, we must be cautious with the administration of anesthetics containing vasoconstrictors in 
patients with cardiovascular diseases.
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Introduction
An essential factor which determines a successful caus-
al periodontal treatment is the administration of good-
quality local anesthesia (LA). Though mepivacaine 
has been traditionally used as the dental anesthetic of 
choice, clinically potent local anesthetic substances, 
such as mepivacaine and articaine, are used in combi-
nation with vasoconstrictors. Vasoconstrictors, mainly 
adrenaline or epinephrine, contribute to successful LA 
as they increase the depth and duration of analgesia. 
Such effect of epinephrine on mepivacaine or articaine-
based LA solutions has already been demonstrated. (1) 
Vasoconstrictors also promote hemostasis and are rou-
tinely incorporated in most commercial preparations. 
(2-4) Furthermore, by concentrating the LA agent at the 
infiltration site, the vasoconstrictor diminishes the risk 
for systemic side effects of LA.
Physiological responses associated with local anesthet-
ics containing a vasoconstrictor include changes in 
heart rate and blood pressure (5-7), dysrrhythmias (8, 
9), ischemic alterations (10,11), endogenous catecho-
lamines release (12), endocrine response to surgery, 
and hypokalemia (13,14). These changes are regulated 
by the net balance between sympathetic and parasym-
pathetic activity, and both stress and pain will further 
modify autonomic response (15,16).
When these vasoconstrictor-induced physiological re-
sponses exceed the normal range, the risk of morbidity 
or even mortality increases. This is of special relevance 
in the case of cardiovascular patients. Although most 
current literature accepts that adrenaline has a safety 
range (17,18), its threshold in cardiovascular patients is 
not clear yet. (19,20)
Although the information available as regards the car-
diovascular response to dental LA with articaine and 
epinephrine and with mepivacaine with epinephrine is 
limited to healthy patients (21,22), it may still be of val-
ue to cardiologists, primary care physicians, surgeons 
and dentists when it comes to select a local anesthetic 
solution for cardiovascular patients. 
The purpose of the present study is to examine the he-
modynamic response to four LA solutions in cardiovas-
cular patients: Articaine 40mg with epinephrine 0.5mg 
%, articaine 40mg with epinephrine 1mg %, mepi-
vacaine 30mg without epinephrine and mepivacaine 
20mg with epinephrine 1mg %. The hypothesis is that 
the synergy of a short half-life time LA agent with a 
proper concentration of epinephrine would be safer for 
cardiovascular patients. 
Material and Methods  
Study design and patients selection
A prospective, randomized, single-blinded, cross-over, 
controlled comparative study was performed at the De-
partment of Special Care in Dentistry, Seville Univer-
sity, Faculty of Odontology during 2009. The study was 
conducted with the approval of the University of Seville 
Ethics Committee and in accordance with the Declara-
tion of Helsinki.
All patients gave their informed consent to take part in 
the study prior to the initiation of the dental treatment. 
Randomization was achieved by using a computer-
generated random number list. Ten patients with car-
diovascular disease who met the inclusion criteria were 
enrolled in the study.
The inclusion criteria were the following: (a) control-
led hypertension (HTN) with blood pressure values ≤ 
160/100 mm Hg; (b) ischemic heart disease (IHD) in-
cluding stable angina pectoris, post-myocardial infarc-
tion (≥ 6 months); (c) chronic periodontitis affecting the 
four quadrants of the oral cavity. 
Exclusion criteria comprised: (a) cardiovascular insta-
bility including unstable angina pectoris, recent myo-
cardial infarction (≤ 6 months), refractory dysrrhyth-
mias, untreated or uncontrolled hypertension, untreated 
or uncontrolled CHF, uncontrolled hyperthyroidism; (b) 
uncontrolled diabetes mellitus; (c) sulphite sensitivity; 
(d) steroid-dependent asthma; (e) pheochromacytoma; 
(f) tricyclic antidepressant treatment; (g) previous his-
tory of psychiatric disorder, chronic use of central nerv-
ous system depressants or antidepressants or mental 
instability. 
All patients underwent clinical and radiographic exami-
nation (periodontal charting and orthopantomography). 
Patients who presented with chronic periodontitis affect-
ing the four quadrants of the oral cavity treatable with 
etiological periodontal therapy (root planning) were ran-
domly allocated in order to determine the order in which 
each of the anesthetics would be applied to the different 
quadrants.  Root planning was programmed following 
a weekly schedule for each of the quadrants. In each of 
the treatment arms, a different LA solution was used: 
(a) mepivacaine 30 mg without epinephrine (Normon, 
Spain) total dose: 108 mg of mepivacaine chlorhydrate; 
(b) articaine 40 mg with epinephrine 0.5mg% (Normon, 
Spain) total dose: 144 mg articaine hydrochloride with 
0.018 mg of epinephrine; (c) articaine 40 mg with epine-
phrine 1 mg% (Normon, Spain) total dose: 144mg ar-
ticaine hydrochloride with 0.036mg of epinephrine, and 
(d) mepivacaine 20mg with epinephrine 1mg% (Inibsa, 
Spain) total dose: 72mg mepivacaine chlorhydrate with 
0.036 mg of epinephrine. We used a cross-over study 
design with a washing period of one week.
Treatment protocol
The study time frame for each subject comprised a base-
line period of 5 minutes followed by LA injection. An-
esthesia was carefully induced with aspiration and slow 
injection of anesthetic. All patients were administered 
a standard dose of 3.6 mL. A minimum of 5 minutes 
was necessary to achieve LA effectiveness. Treatment 
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lasted until completion of dental procedure (one session 
of root planning and polishing per quadrant). Patients 
were asked to remain seated for several minutes after 
the completion of the treatment. The same two investi-
gators attended every treatment session, one of them in 
charge of the treatment and the other one in charge of 
monitoring and data recording.
Monitoring 
A non-invasive monitor (Avant 2020 pulsioximeter, Non-
in Medical Inc. Minnessotta, USA) was used to record 
systolic, diastolic and mean blood pressure (sysBP, diaBP, 
meanBP, respectively) at 5-minute intervals. Oxygen blood 
saturation (SO2) and heart rate (HR) were continuously 
recorded. Online transmission of data from the pulsioxi-
meter to a personal computer was mediated with software 
nVISION v. 5.1e (Nonin Medical Inc. Minnessotta, USA). 
Monitoring began at the onset of the baseline period and 
continued every 5 minutes after completion of the peri-
odontal treatment.
Statistics
Standard time points and time intervals were defined: 
(a) Baseline: beginning of monitoring; (b) Baseline + 5 
minutes: end of stabilization period; (c) LA: injection 
timing; (d) LA +  5 minutes: 5 minutes after injection; 
(e) Treatment: onset of dental treatment; (f) End: com-
pletion of treatment.
The hemodynamic indices measured at the above men-
tioned points were used to carry out the descriptive sta-
tistic analysis (means, SD). Demographic parameters 
and hemodynamic indices of the 4 treatment arms were 
compared using t-test and analysis of variance (ANOVA, 
Bonferroni post-hoc test). Kolmogorov-Smirnov test 
was used to confirm the normal distribution of data. 
Results
Baseline characteristics of patients were compared in the 
two groups as regards mean age (63±12.5 yrs), jaw under 
treatment and duration of treatment (26.38±9.9 minutes).
Programmed dental procedure was completed in all 10 pa-
tients. No severe adverse effects were observed in any of the 
patients. Clinical data of patients are shown in table 1.
Hemodynamic indices of HR, sysBP and SO2 at various 
Patient Baseline pathology        Other pathology Treatment 
1 
Hypertension (140-80) Pacemaker 
Previous angina Hypercholesterolemia 
Isosorbida 50mg/day 
Omeprazol 20mg/day 
AAS 100mg/day 
2 Hypertension (140-80) Hypercholesterolemia 
Captopril 50mg/day 
Simvastatina 40mg/day 
Calcio y Vitamina D 3g/day 
3 
Hypertension (140-60) 
Previous CVA related to 
hypertensive crisis 
Hyperlipidemia 
Double degenerative aortic 
lesion 
Irritable bowel syndrome 
Captopril  50mg/day 
4 Hypertension (140-80)  
Captopril  50mg/day 
AAS 100mg/day 
5 Hypertension (130-90)  Enalapril 10 mg/day 
6 
Hypertension (130 - 90) Previous 
CVA 
Hyperlipidemia 
Simvastatina 40mg/day 
Ranitidina 300mg/day 
Enalapril 10 mg/day 
7 Hypertension (130-70) Diabetes Mellitus Enalapril 10 mg/day 
8 
Hypertension (140-70) 
Previous angina 
Hypercholesterolemia 
Diabetes 
Irbesartán 150mg/day 
Lovastatina 20mg/day 
Metformina 2,5g/day 
Insulina isofánica (NPH) 100ui/ml 
AAS 100mg/day 
Omeprazol 20mg/day 
9 Hypertension (140-80) Alcoholic liver disease 
Captopril  50mg/day   Omeprazol 
20mg/day 
Timolol 5mg/day 
10 Hypertension (130-70)   Enalapril 10mg/day 
 
Table 1. Baseline pathology, other pathologies and baseline treatment in the patients under study. 
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time points and time intervals showed no statistical dif-
ferences when comparing both groups. The group receiv-
ing Mepivacaine 2% with epinephrine 1:100,000 showed 
statistical differences with the rest of the groups as we 
observed increased diaBP levels at the stabilization pe-
riod (p< 0.038) and meaBP (p< 0.01) at the stabilization 
period and in the treatment period (p< 0.039) (Table 2).
To analyse the effect of epinephrine on the anesthetics, 
clinical data were divided into two study groups: with 
(n= 30) and without (n=10) adrenaline. Hemodynamic 
indices of HR (p< 0.039), sysBP (p< 0.046), diaBP (p< 
0.046), at various time points and time intervals (treat-
ment and stabilization periods) were statistically differ-
ent in both groups (Table 3).
   Variable Group 
Period 
      Baseline        p 
Increase 
Stabilization 
– Baseline 
      p 
Increase 
Treatment – 
Baseline 
        p 
Increase 
Treatment - 
Stabilization 
 
        p 
 
Heart Rate 
(ppm) 
1 82,20 ± 14,32 
  p= 0,337 
-2,70 ± 1,88 
p=0,950 
-3,90 ± 3,69 
 p= 0,255 
-1,20 ± 2,30  
 
p=0,115 
2 71,50 ± 9,12 -2,00 ± 3,91 1,50 ± 3,37 0,50 ± 1,50 
3 79,80 ± 15,92 -2,40 ± 3,06 -2,60 ± 4,22 -0,20 ± 2,70 
4 80,70 ± 15,84 -2,20 ± 1,61 -0,70 ± 3,43 1,50 ± 3,10 
Systolic 
Arterial 
Pressure 
(mmHg) 
1 141,20 ± 21,14 
p= 0,870 
-5,40 ± 12,03 
p=0,236 
-6,30 ± 8,20 
p= 0,484 
-0,90 ± 8,03  
 
p=0,123 
2 141,90 ± 14,01 -0,90 ± 6,11 0,40 ± 8,16 1,30 ± 5,47 
3 138,40 ± 28,77 -1,70 ± 17,21 0,00 ± 12,79 1,70 ± 9,59 
4 134,60 ± 19,53 5,80 ± 10,47 -1,40 ± 12,55 -7,20 ± 11,93 
Diastolic 
Arterial 
Pressure 
(mmHg) 
1 80,60 ± 13,76 
p= 0,163 
-1,20 ± 6,05 
p=0,038 
-2,90 ± 8,80 
p= 0,057 
-1,70 ± 4,57  
 
p=0,118 
2 82,70 ± 13,13 -2,30 ± 3,74 -0,70 ± 5,65 1,60 ± 4,40 
3 83,40 ± 19,09 -4,80 ± 7,33* -7,90 ± 7,57 -3,10 ± 5,04 
4 70,40 ± 8,94 7,20 ± 15,63* 0,10 ± 4,65 -7,10 ± 13,51 
 
Mean Blood 
Pressure 
(mmHg) 
1 97,90 ± 14,79 
p= 0,362 
-5,40 ± 7,26* 
p=0,010 
-4,60 ± 6,39 
p= 0,233 
0,80 ± 5,55  
 
p=0,039 
2 102,60 ± 11,16 -1,80 ± 3,73 -0,30 ± 5,96 1,50 ± 4,50* 
3 102,80 ± 18,68 -4,20 ± 8,12$ -5,00 ± 6,49 -0,80 ± 6,16 
4 92,80 ± 10,96 5,50 ± 9,13*$ -0,60 ± 7,16 -6,10 ± 8,00* 
 
Partial Oxygen 
Saturation 
(%) 
1 95,00 ± 2,00 
p= 0,293 
-0,30 ± 0,67 
p=0,834 
-0,20 ± 0,91 
p= 0,283 
0,10 ± 0,87  
 
p=0,119 
2 94,40 ± 1,64 -0,20 ± 1,03 -0,90 ± 0,99 -0,70 ± 0,48 
3 95,40 ± 1,95 -0,40 ± 1,07 -0,60 ± 1,07 -0,20 ± 1,03 
4 93,90 ± 1,72 -0,60 ± 1,17 -1,10 ± 1,28 -0,50 ± 0,52 
 
 
 
Variable 
 
 
Group 
Period 
 
Baseline 
 
p 
Increase 
Stabilization 
– Baseline 
 
p 
Increase 
Treatment – 
Baseline 
 
p 
Increase 
Treatment - 
Stabilization 
 
p 
Heart  Rate 
(ppm) 
1 82,20 ± 14,32  
p= 0,353 
-2,70 ± 1,88  
p=0,616 
-3,90 ± 3,69  
p= 0,039 
-1,20 ± 2,30  
p=0,108 2 77,33 ± 14,14 -2,20 ± 2,91 -1,60 ± 3,65 0,60 ± 2,54 
Systolic Arterial 
Pressure 
(mmHg) 
1 141,20 ± 21,14  
p=0.709 
-5,40 ± 12,03  
p=0,046 
-6,30 ± 8,20  
p= 0,125 
-0,90 ± 8,03  
p=0,887 2 138,30  ± 21,10 1,07 ± 12,21 -0,33 ± 11,00 -1,40 ± 9,97 
Diastolic 
Arterial 
Pressure 
(mmHg) 
1 80,60 ± 13,76  
p=0,746 
-5,40 ± 7,26  
p=0,046 
-4,60 ± 6,39  
p=0,283 
0,80 ± 5,55  
p=0,291 
2 78,83 ± 15,11 -0,17 ± 8,26 -1,97 ± 6,69 -1,80 ± 6,96 
Mean Blood 
Pressure 
(mmHg) 
1 97,90 ± 14,79  
p=0,778 
-1,20 ± 6,05  
p=0,640 
-2,90 ± 8,80  
p=0,980 
-1,70 ± 4,57  
p=0,702 2 99,40 ± 14,38 0,03 ± 11,15 -2,83 ± 6,91 -2,87 ± 9,14 
Partial Oxygen 
Saturation 
(%) 
1 95,00  ± 2,00  
p=0,530 
-0,30 ± 0,67  
p=0,890 
-0,20 ± 0,91  
p=0,480 
0,10 ± 0,87  
p=0,283 2 94,57  ± 1,83 -0,40 ± 1,07 -0,87 ± 1,10 -0,47 ± 0,73 
 
Table 2. Values of the different variables studied in the four study groups during baseline, stabilization and treatment period. (Groups: 1.- Mepi-
vacaine chlorhydrate at 3% 2.- Articaine hydrochloride  40 mg + epinephrine 5mg% 3.- Articaine hydrochloride 40 mg + epinephrine 1 mg% 
4.- Mepivacaine chlorhydrate at 2% + epinephrine 1:100.000; n=10 in all of them).
Table 3. Values of the different variables in the groups of anesthetics with and without vasoconstrictors during baseline, stabilization and treat-
ment periods. Group without vasoconstrictor = Group 1 (n=10); Group with vasoconstrictor = Group 2 (n = 30).
(* y $ show statistically significant differences among groups).
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Discussion
The use of local anesthetics associated to vasoconstric-
tors is somewhat controversial among the professionals 
of odontology because, together with the beneficial ef-
fects of such combinations, other side effects have been 
detected, mainly of cardiovascular nature (5-7).
Such side effects may be adverse, although the use of 
these substances is not contraindicated in healthy sub-
jects whenever the adequate doses and correct admin-
istration procedure is followed. In fact, most studies on 
the alterations of vascular parameters associated with 
the use of dental anesthetics containing vasoconstric-
tors have been carried out in healthy subjects, which 
would explain the possible bias observed in the results 
(23-27).
In Western civilization, the number of cardiovascular 
patients who visit a dental clinic is increasing. Very few 
studies have so far analysed the effect of dental anes-
thetics containing vasoconstrictors on cardiovascular 
patients (28,29). Therefore, it is of the utmost impor-
tance to determine, by means of controlled trials, the 
effect such substances may have on this type of patients 
in order to allow the safe use of anesthetics with vaso-
constrictors in a greater number of patients.  
The criterion used to group patients with cardiovascu-
lar diseases is not homogeneous in the different studies 
published so far. The present study analyses a 100% of 
patients with arterial hypertension. Conrado et al. (28) 
study a sample of 100% of patients with heart failure. 
Elad et al. (29) do not report the disease rate in their 
sample of patients, but use controlled arterial hyperten-
sion as inclusion criteria. 
In the present study, alterations in heart rate were not 
significant when we compared the four study groups. 
Nevertheless, when we compared the use of anesthet-
ics without and with vasoconstrictors, in the first group 
we observed a significant decrease in heart rate in com-
parison to the second group. This effect is similar to 
the one reported by Matthews et al. (30), who detected 
a decrease of 10 ppm. In our sample, we have observed 
a reduction of 4 ppm. In any case, heart rate does not 
increase above baseline levels and therefore it always 
remains within a safe interval throughout the treatment 
period. 
As regards arterial pressure, we have observed few sig-
nificant alterations, mainly referring to an increase of 
diastolic arterial pressure and mean blood pressure dur-
ing the stabilization period in comparison with baseline 
levels. Diastolic arterial pressure and mean blood pres-
sure increased significantly in group 4 (mepivacaine 
chlorhydrate at 2% + epinephrine 1:100,000) in com-
parison to the rest of groups. If we focus on the first 
three study groups (mepivacaine chlorhydrate at 3%; 
40 mg articaine hydrochloride + 0.5 mg% epinephrine; 
40mg articaine hydrochloride + 1mg % epinephrine), 
the alterations detected are similar to those reported by 
Conrado et al. (28), Neves et al. (31) or Elad et al. (29). 
Increases observed in the fourth group (mepivacaine 
chlorhydrate at 2% + epinephrine 1:100,000) have not 
been reported in the literature as this type of anesthetic 
has not been analysed. As a result, we must be cautious 
when administering this anesthetic combination to car-
diovascular patients.
When we classify the results obtained according to the 
use or not of vasoconstrictors, we observed alterations 
in diastolic and systolic blood pressure between the 
baseline period and the stabilization period. This would 
confirm the critical nature of this period, already ob-
served in previous reports (28,31). 
As regards oxygen partial pressure, our results do not 
show remarkable alterations when comparing the dif-
ferent study groups, similarly to what Matthews et al. 
(30) had already reported. 
Finally, we must add some points about the different 
treatment regimes analysed. All of them have been well 
tolerated by patients. Even in the case of cardiovascular 
patients, some of them suffering from more than one 
disease, no adverse side effects have been detected. As 
a result, and considering the results obtained, we can 
confirm that these treatments are very safe in all cases.
Yet, as has been clearly demonstrated, the combination 
of anesthetics and vasoconstrictors provokes cardiovas-
cular alterations which could have serious clinical con-
sequences in patients with more severe pathologies than 
the ones here studied. 
It would be advisable to increase the level of complex-
ity of the techniques used to obtain data (use of Holter, 
electrocardiogram, cardiac enzyme study, etc.) in order 
to identify ischemic events of short duration. However, 
we should also justify the necessity of these complex 
techniques. 
In our opinion, more complex studies would be justi-
fied in the case of severe cardiovascular patients as al-
terations which are unimportant in the case of healthy 
subjects could have clinical relevance in these patients. 
Nevertheless, such studies should be accompanied by 
greater safety measures in the case of patients more se-
verely compromised. 
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